Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Return on Capital Employed came in at 45.83% in Q1 2026, up 66.0% YoY from 27.61% in Q1 2025, and up 8.85% on a QoQ basis from 50.28% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 6 years of Return on Capital Employed data on file, last reported at 45.83% in Q1 2026.
- Quarterly Return on Capital Employed rose 66.0% year-over-year to 45.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45.83% (up 66.0% YoY) and the FY2025 annual result came in at 49.34%, up 612.0% from the prior year.
- Return on Capital Employed improved to 45.83% in Q1 2026, from 50.28% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 35.5% in Q1 2022 to a low of 70.8% in Q1 2024.
- A 5-year average of 52.55% and a median of 51.61% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 2542 bps — and 2025, when it surged 2431 bps.
- Tracing RXRX's Return on Capital Employed over 5 years: stood at 44.18% in 2022, then slumped by 44 bps to 63.75% in 2023, then climbed by 17 bps to 53.22% in 2024, then gained by 6 bps to 50.28% in 2025, then advanced by 9 bps to 45.83% in 2026.
- The last three Return on Capital Employed figures came in at 45.83% (Q1 2026), 50.28% (Q4 2025), and 60.51% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -47.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.05% |
| Mar 31, 2026 | -45.83% |
| Dec 31, 2025 | -50.28% |
| Sep 30, 2025 | -60.51% |
| Jun 30, 2025 | -57.00% |
| Mar 31, 2025 | -46.48% |
| Dec 31, 2024 | -53.22% |
| Sep 30, 2024 | -61.37% |
| Jun 30, 2024 | -68.08% |
| Mar 31, 2024 | -70.80% |
| Dec 31, 2023 | -63.75% |
| Sep 30, 2023 | -56.27% |
| Jun 30, 2023 | -51.61% |
| Mar 31, 2023 | -45.37% |
| Dec 31, 2022 | -44.18% |
| Sep 30, 2022 | -44.67% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.50% |
| Dec 31, 2021 | -31.09% |
| Sep 30, 2021 | -22.56% |